Navigation Links
New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease
Date:10/31/2011

propriate therapy.

Hepatitis B Reactivation

Use of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating CIMZIA therapy. Exercise caution in prescribing CIMZIA for patients identified as carriers of HBV, with careful evaluation and monitoring prior to and during treatment. In patients who develop HBV reactivation, discontinue CIMZIA and initiate effective anti-viral therapy with appropriate supportive treatment.

Neurologic Reactions

Use of TNF blockers, including CIMZIA, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA. Exercise caution in considering the use of CIMZIA in patients with these disorders.

Hematologic Reactions

Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with CIMZIA. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on CIMZIA. Consider discontinuation of CIMZIA therapy in patients with confirmed significant hematologic abnormalities.

Drug Interactions

An increased risk of serious infections has been seen in clinical trials of other TNF blocking
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
2. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
3. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
4. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
5. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
6. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
7. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
8. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
9. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
10. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
11. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
(Date:10/20/2014)... NEW YORK and RALEIGH, N.C., Oct. 20, ... the Hereditary Neuropathy Foundation (HNF), both philanthropies, announced ... develop drug candidates for the treatment of the ... BioPontis Alliance announced its alliance model ... is a first demonstration of a collaborative model ...
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... WASHINGTON, June 8, 2011 /PRNewswire/ -- A ... (AUA) Annual Meeting shows the less-invasive Pro-Vas® occlusion as ... The clinical study results were presented by Douglas ... AUA Annual Meeting. The AUA meeting is the world,s ...
... 2011 On June 7, 2011, Vycor Medical, Inc. ... in Units comprising Preferred Shares and Warrants (the "Units") ... pursuant to the terms of separate Series C Convertible ... of the Investors. This sale is an initial closing ...
Cached Medicine Technology:Phase I Pro-Vas® Effectiveness Study Presented at AUA Meeting 2Vycor Medical, Inc. Completes Equity Capital Raise 2Vycor Medical, Inc. Completes Equity Capital Raise 3
(Date:10/19/2014)... October 20, 2014 The leading ... ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best ... platforms for those who want to buy high ... time. , The IT manager of Top10BestSEOHosting.com says, ... most recommended suppliers for everyone. A lot of ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many kinds ... designs of 2014 mother of the bride dresses ... offered with big discounts, up to 70% off. All ... enjoy this special offer. , Owing to the ... one of the leading brands in the global market. ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Stephen T. Greenberg, ... been nominated for the 10th consecutive year as one of ... Dr. Greenberg was also been nominated as the best provider ... also nominated as best Day Spa and best Laser Treatment ... December 14th and readers can vote for the contest once ...
(Date:10/19/2014)... 20, 2014 – The U.S. Government has initiated ... Alzheimer,s disease by 2025. However, a workgroup of ... research milestones in the U.S. Government,s National Plan ... scope, increased in scale, and adequately funded in ... of proposals by the workgroup to enlarge and ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... boost survival, German study shows , MONDAY, June ... performing radical hysterectomy in early-stage cervical cancer patients ... tumor recurrence, a German study shows. , The ... modified version of traditional radical hysterectomy. But this ...
... Continuing Education Lectures for Healthcare Professionals , , ... challenging diagnosis which carries a poor prognosis and appears ... signaling and tumor suppressor pathways. While current treatment options ... for patients. In order to do this, healthcare professionals ...
... AUGUSTA, Ga. Even while their blood pressures are ... of a hormone known to increase pressures as well ... Medical College of Georgia researchers looking at 126 healthy ... the hormone aldosterone highest among the overweight males. Early ...
... Seabrook House Inc. is one of the few treatment centers ... House is helping families find the courage to recover from their ... of alcohol and drug treatment for the families. , ... for more professionals on staff to accommodate the higher patient census ...
... Support Award to Recognize Critical Role of Pharmacists in Alzheimer,s ... June 1 Eisai Inc., in coordination with the ... caregivers across America to nominate local pharmacists for the 2009 ... ecognition of E xcellence.) Pharmacy Award. This award ...
... combined with standard chemotherapy, an international Phase III trial ... progression-free survival for patients with advanced non-small cell lung ... M. D. Anderson Cancer Center. The findings, presented ... meeting, mark the first clinical benefit of a small ...
Cached Medicine News:Health News:Adult Glioblastoma: Best Approaches to a Challenging Diagnosis 2Health News:Overweight male teens with normal blood pressures showing signs of heart damage 2Health News:Overweight male teens with normal blood pressures showing signs of heart damage 3Health News:Seabrook House, Inc. Successful in Recession Due to the Acceptance of Most Insurances; Expands With New Hires Due to the Growth of the Company 2Health News:Seabrook House, Inc. Successful in Recession Due to the Acceptance of Most Insurances; Expands With New Hires Due to the Growth of the Company 3Health News:Call for Nominations for the 2009 C.A.R.E. Pharmacy Award 2Health News:Call for Nominations for the 2009 C.A.R.E. Pharmacy Award 3Health News:Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 2Health News:Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: